Increased Lyso-Gb1 Levels in an Obese Splenectomized Gaucher Disease Type 1 Patient Treated with Eliglustat: Unacknowledged Poor Compliance or Underlying Factors
Authors:
- Evelina MainesEMEvelina Maines
- Roberto FranceschiRoberto Franceschi
- Giacomo LuppiGLGiacomo Luppi
- Giacomo MarchiGMGiacomo Marchi
- Giovanni PiccoliGPGiovanni Piccoli
- Nicola VitturiNVNicola Vitturi
- Massimo SoffiatiMSMassimo Soffiati
- Annalisa CampomoriACAnnalisa Campomori
- Silvana Anna Maria UrruSUSilvana Anna Maria Urru
Open Access
- 23 June 2025
- journal article
- case report
- Published by MDPI AG in Metabolites
- Vol. 15 (7) , 427
Abstract
Eliglustat (Cerdelga®) is a potent and specific inhibitor of the enzyme glucosylceramide synthase and serves as a substrate reduction therapy for adult patients with Gaucher disease type 1 (GD1). It prevents the accumulation of several lipids, including glucosylsphingosine (also known as Lyso-Gb1). In addition to its role in diagnostics, Lyso-Gb1 has been proven to be a reliable biomarker for assessing disease severity and monitoring treatment efficacy. We present the case of an obese, splenectomized GD1 patient on long-term enzyme replacement therapy (ERT) who reported worsening fatigue and showed a progressive increase in Lyso-Gb1 levels after switching treatment from ERT to eliglustat. We provide a discussion of the potential clinical factors contributing to this outcome. As seen with ERT, Lyso-Gb1 levels during eliglustat treatment appear to respond earlier than other biochemical and clinical parameters. An increase in Lyso-Gb1 may signal early compromised clinical efficacy of the treatment. Data on biochemical and clinical outcomes in splenectomized or obese patients treated with eliglustat are limited, and the role of specific genotypes requires further clarification. The variability in responses to eliglustat highlights the complexity of GD and underscores the need for personalized approaches to treatment and monitoring.Keywords
Funding Information
- Azienda Provinciale per i Servizi Sanitari of Trento (Italy)
- Universities of Verona and Padua
This publication has 32 references indexed in Scilit:
- Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsAmerican Journal of Hematology, 2021
- Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trialAmerican Journal of Hematology, 2018
- Glucosylsphingosine is a key biomarker of Gaucher diseaseAmerican Journal of Hematology, 2016
- Epigenetic Changes in Gene Expression for Drug‐Metabolizing Enzymes and TransportersPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supplyBlood Cells, Molecules, and Diseases, 2011
- Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortageBlood Cells, Molecules, and Diseases, 2011
- Management of non‐neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoringJournal of Inherited Metabolic Disease, 2008
- Haplotype analysis suggests a single Balkan origin for the Gaucher disease [D409H;H255Q] double mutant alleleHuman Mutation, 2008
- Correlation among Genotype, Phenotype, and Biochemical Markers in Gaucher Disease: Implications for the Prediction of Disease SeverityMolecular Genetics and Metabolism, 2002
- A 27-Year experience with splenectomy for Gaucher's diseaseThe American Journal of Surgery, 1991